Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
Following the initial success of imatinib as frontline therapy for chronic myeloid leukemia (CML), several second-generation therapeutics have been developed with increased potency and the ability to inhibit the majority of imatinib-resistant mutations. Here, we review the current knowledge about the target specificity of the two new inhibitors nilotinib and dasatinib in comparison to imatinib, including the recent large-scale chemical proteomics screens.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Dasatinib, although relatively specific for ABL, BCR-ABL and the SFKs, it possesses a broad-spectrum of inhibition of kinases including Kit, PDGFR, EphA receptors and several others (Hantschel et al., 2008).”
From Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab (2011) · cites this paper as Hantschel et al., 2008
In the citing paper
“We recognize that while dasatinib primarily targets SFKs and BCR-ABL, it also inhibits other kinases including c-KIT, PDGFRβ, EPHA2, among others [41].”
From Co-targeting SRC overcomes resistance to BRAF inhibitors in colorectal cancer (2025) · cites this paper as [41]
Citations
Cites
Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia
Druker, B. J., Guilhot, F., O'Brien, S. G., Gathmann, I., Kantarjian, H., Gattermann, N., Deininger, M. W. N., Silver, R. T., Goldman, J. M., Stone, R. M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062867 · Cited by 3,488 · cited 1×
“In addition to these cases of so-called secondary imatinib resistance, approximately 15% of patients with chronic phase CML do not achieve a complete cytogenetic response on imatinib at the standard dose of 400 mg [4].”
BackgroundGlobal Survey of Phosphotyrosine Signaling Identifies Oncogenic Kinases in Lung Cancer
Rikova, K., Guo, A., Zeng, Q., Possemato, A., Yu, J., Haack, H., Nardone, J., Lee, K., Reeves, C., Li, Y., et al. (2007) · Cell · doi:10.1016/j.cell.2007.11.025 · Cited by 2,317 · cited 1×
“DDR1 is emerging as an important player in immunity as well as many tumours, in particular in non-small cell lung cancer [16].”
BackgroundA small molecule–kinase interaction map for clinical kinase inhibitors
Fabian, M. A., Biggs, W. H., Treiber, D. K., Atteridge, C. E., Azimioara, M. D., Benedetti, M. G., Carter, T. A., Ciceri, P., Edeen, P. T., Floyd, M., et al. (2005) · Nature Biotechnology · doi:10.1038/nbt1068 · Cited by 1,892 · cited 1×
“Here, a library of *150 to 200 selected kinases are expressed as phage particle fusion proteins and the binding affinity of kinase inhibitors is inferred by competition assays [9,10].”
BackgroundOverriding Imatinib Resistance with a Novel ABL Kinase Inhibitor
Shah, N. P., Tran, C., Lee, F. Y., Chen, P., Norris, D., & Sawyers, C. L. (2004) · Science · doi:10.1126/science.1099480 · Cited by 1,796 · cited 2×
“Of these second generation inhibitors, dasatinib (Sprycel, BMS-354825, Bristol-Myers Squibb) has been approved for the treatment of adults with CML and BCR-ABL-positive acute lymphoblastic leukemia with imatinib resistance or intolerance to previous therapy [5].”
BackgroundCharacterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl
Weisberg, E., Manley, P. W., Breitenstein, W., Brüggen, J., Cowan-Jacob, S. W., Ray, A., Huntly, B., Fabbro, D., Fendrich, G., Hall-Meyers, E., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.01.007 · Cited by 1,492 · cited 2×
“imatinib-resistant forms with the exception of the T315I (gatekeeper) mutation [5,6].”
BackgroundThe development of imatinib as a therapeutic agent for chronic myeloid leukemia
Deininger, M., Buchdunger, E., & Druker, B. J. (2005) · Blood · doi:10.1182/blood-2004-08-3097 · Cited by 1,253
Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors
Bantscheff, M., Eberhard, D., Abraham, Y., Bastuck, S., Boesche, M., Hobson, S., Mathieson, T., Perrin, J., Raida, M., Rau, C., et al. (2007) · Nature Biotechnology · doi:10.1038/nbt1328 · Cited by 1,034
Structural Basis for the Autoinhibition of c-Abl Tyrosine Kinase
Nagar, B., Hantschel, O., Young, M. A., Scheffzek, K., Veach, D., Bornmann, W., Clarkson, B., Superti-Furga, G., & Kuriyan, J. (2003) · Cell · doi:10.1016/s0092-8674(03)00194-6 · Cited by 879 · cited 2×
“Therefore, BCR-ABL is a suitable drug target, and research on this kinase cumulated in the discovery of imatinib (Gleevec1, STI-571), which is currently frontline therapy in CML. Imatinib is a relatively weak inhibitor of BCRABL with an IC50 in the upper nano-molar range, but has remarkable specificity, targeting only…”
BackgroundSelf-citationRix, U., Hantschel, O., Dürnberger, G., Remsing Rix, L. L., Planyavsky, M., Fernbach, N. V., Kaupe, I., Bennett, K. L., Valent, P., Colinge, J., et al. (2007) · Blood · doi:10.1182/blood-2007-07-102061 · Cited by 671
Self-citationInhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases
Carter, T. A., Wodicka, L. M., Shah, N. P., Velasco, A. M., Fabian, M. A., Treiber, D. K., Milanov, Z. V., Atteridge, C. E., Biggs, W. H., Edeen, P. T., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0504952102 · Cited by 554 · cited 2×
“Also in the case of dasatinib, kinases such as the ABL and SRC had been already confirmed and more had been postulated to be potential targets [9].”
Background
Research works printed but not linked: 1
- le Coutre P, Blood
Cited by
Stem Cell Factor Receptor/c-Kit: From Basic Science to Clinical Implications
Lennartsson, J., & Rönnstrand, L. (2012) · Physiological Reviews · doi:10.1152/physrev.00046.2011 · Cited by 825
Trends in kinase drug discovery: targets, indications and inhibitor design
Attwood, M. M., Fabbro, D., Sokolov, A. V., Knapp, S., & Schiöth, H. B. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00252-y · Cited by 779
Zhong, Q., Xiao, X., Qiu, Y., Xu, Z., Chen, C., Chong, B., Zhao, X., Hai, S., Li, S., An, Z., et al. (2023) · MedComm · doi:10.1002/mco2.261 · Cited by 442
Role of ABL family kinases in cancer: from leukaemia to solid tumours
Greuber, E. K., Smith-Pearson, P., Wang, J., & Pendergast, A. M. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3563 · Cited by 432
Discoidin domain receptor tyrosine kinases: new players in cancer progression
Valiathan, R. R., Marco, M., Leitinger, B., Kleer, C. G., & Fridman, R. (2012) · Cancer and Metastasis Reviews · doi:10.1007/s10555-012-9346-z · Cited by 383
“and thus, many of the TKIs used today in the clinic are known to target multiple kinases including DDRs [164–166].”
Past, present, and future of Bcr-Abl inhibitors: from chemical development to clinical efficacy
Rossari, F., Minutolo, F., & Orciuolo, E. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0624-2 · Cited by 371
“Nilotinib (AMN107) shows greater potency and effectiveness against almost the totality of resistanceconferring mutations (see Table 1 for IC50 values), except for T315I and few others, in newly diagnosed Ph+ CML patients [22, 23].”
BackgroundDenduluri, S. K., Idowu, O., Wang, Z., Liao, Z., Yan, Z., Mohammed, M. K., Ye, J., Wei, Q., Wang, J., Zhao, L., et al. (2015) · Genes & Diseases · doi:10.1016/j.gendis.2014.10.004 · Cited by 331
“For example, IGFBP-2 directly interacts with integrins and the extracellular matrix to stimulate growth.61 IGFBP-2 appears to be causally associated with NSCLC resistance to dasatinib, a BCR-ABL and SRC family TKI.62,63 Furthermore, focal adhesion kinase (FAK), which is downstream of IGFBP-2 and integrin binding, is c…”
BackgroundInfluentialStepanenko, A. A., & Dmitrenko, V. V. (2015) · Gene · doi:10.1016/j.gene.2015.08.009 · Cited by 315
“…LCK, and LYN), as well as RAF kinase family members (BRAF and CRAF) and the oxidoreductase NQO2 at the therapeutic concentrations (Anastassiadis et al., 2011; Breitkopf et al., 2010; Davis et al., 2011; Hantschel et al., 2008; Kitagawa et al., 2013; Packer et al., 2011; Steegmann et al., 2012).”
BackgroundGlobal target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells
Remsing Rix, L. L., Rix, U., Colinge, J., Hantschel, O., Bennett, K. L., Stranzl, T., Müller, A., Baumgartner, C., Valent, P., Augustin, M., et al. (2009) · Leukemia · doi:10.1038/leu.2008.334 · Cited by 284
Self-citationVascular safety issues in CML patients treated with BCR/ABL1 kinase inhibitors
Valent, P., Hadzijusufovic, E., Schernthaner, G.-H., Wolf, D., Rea, D., & le Coutre, P. (2015) · Blood · doi:10.1182/blood-2014-09-594432 · Cited by 283
Protein kinase inhibitors: contributions from structure to clinical compounds
Johnson, L. N. (2009) · Quarterly Reviews of Biophysics · doi:10.1017/s0033583508004745 · Cited by 256
“How do activating mutations in EGFR lead to greater drug sensitivity? A number of mutations have been identified that affect the catalytic site (Chan et al. 2006 ; Shigematsu & Gazdar, 2006). These include an in-frame deletion of exon 19, residues 747–749 (sequence LRE), at the region before the C-helix that accounts…”
BackgroundInfluentialMahul-Mellier, A.-L., Fauvet, B., Gysbers, A., Dikiy, I., Oueslati, A., Georgeon, S., Lamontanara, A. J., Bisquertt, A., Eliezer, D., Masliah, E., et al. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddt674 · Cited by 219
“We then assessed the effect of inhibiting c-Abl activity using three highly specific c-Abl inhibitors: nilotinib, imatinib (ATPcompetitive kinase inhibitors) (60) and GNF-2 (allosteric c-Abl inhibitor) (61).”
MethodSelf-citationDiscoidin domain receptors in disease
Borza, C. M., & Pozzi, A. (2014) · Matrix Biology · doi:10.1016/j.matbio.2013.12.002 · Cited by 205
“Three kinase inhibitors dasatinib (type I), imatinib (type II) and nilotinib (type II), identified initially as inhibitors of tyrosine kinase BCR-ABL, were found to target DDRs in a chemical proteomic profiling study (Bantscheff et al., 2007; Hantschel et al., 2008).”
BackgroundA cellular screen identifies ponatinib and pazopanib as inhibitors of necroptosis
Fauster, A., Rebsamen, M., Huber, K. V. M., Bigenzahn, J. W., Stukalov, A., Lardeau, C.-H., Scorzoni, S., Bruckner, M., Gridling, M., Parapatics, K., et al. (2015) · Cell Death & Disease · doi:10.1038/cddis.2015.130 · Cited by 188
“The target spectra of the latter four have been analyzed previously and show extensive overlap.(45,46) To investigate”
Self-citationInfectious Complications of Biological and Small Molecule Targeted Immunomodulatory Therapies
Davis, J. S., Ferreira, D., Paige, E., Gedye, C., & Boyle, M. (2020) · Clinical Microbiology Reviews · doi:10.1128/cmr.00035-19 · Cited by 187
“BTK is also involved in chemokine-mediated homing and adhesion of chronic lymphocytic leukemia (CLL) cells to the microenvironment, contributing to their maintenance and proliferation (947).”
BackgroundInfluentialFOXM1 (Forkhead box M1) in Tumorigenesis
(2013) · Advances in Cancer Research · doi:10.1016/b978-0-12-407190-2.00016-2 · Cited by 184
Structure, Regulation, Signaling, and Targeting of Abl Kinases in Cancer
Hantschel, O. D. (2012) · Genes & Cancer · doi:10.1177/1947601912458584 · Cited by 180
Self-citationReinwald, M., Silva, J. T., Mueller, N. J., Fortún, J., Garzoni, C., de Fijter, J. W., Fernández-Ruiz, M., Grossi, P., & Aguado, J. M. (2018) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2018.02.009 · Cited by 176
“Imatinib is the only first-line targeted therapy approved for patients with c-Kitepositive gastrointestinal stromal tumours, both as adjuvant therapy after resection and in the advanced/metastatic setting [3,4].”
BackgroundCharting the molecular network of the drug target Bcr-Abl
Brehme, M., Hantschel, O., Colinge, J., Kaupe, I., Planyavsky, M., Köcher, T., Mechtler, K., Bennett, K. L., & Superti-Furga, G. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0900653106 · Cited by 170
“Dasatinib targets the active conformation of Bcr-Abl and has a markedly broader specificity compared with the highly selective nilotinib, which targets a unique inactive Bcr-Abl conformation, as does imatinib (7, 41).”
BackgroundSelf-citationFiore, D., Judson, R. N., Low, M., Lee, S., Zhang, E., Hopkins, C., Xu, P., Lenzi, A., Rossi, F. M. V., & Lemos, D. R. (2016) · Stem Cell Research · doi:10.1016/j.scr.2016.06.007 · Cited by 155
“It is important tomention, however, that Nilotinib potently inhibits other tyrosine kinases, including the ABL kinases, BCR-ABL, KIT and DDR1 (Hantschel et al., 2008), which play important roles in mitosis, cell growth, survival and differentiation.”
BackgroundTyrosine kinase inhibitors as modulators of ABC transporter-mediated drug resistance
Shukla, S., Chen, Z.-S., & Ambudkar, S. V. (2012) · Drug Resistance Updates · doi:10.1016/j.drup.2012.01.005 · Cited by 168
“Some recent reviews have extensively dealt with the interactions of small molecule TKIs with several target kinases in basic and clinical studies (Hantschel et al., 2008; Janne et al., 2009).”
BackgroundGao, M., Duan, L., Luo, J., Zhang, L., Lu, X., Zhang, Y., Zhang, Z., Tu, Z., Xu, Y., Ren, X., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm301824k · Cited by 167
Oncogenic signaling from the hematopoietic growth factor receptors c-Kit and Flt3
Masson, K., & Rönnstrand, L. (2009) · Cellular Signalling · doi:10.1016/j.cellsig.2009.06.002 · Cited by 158
“Dasatinib affects a wide array of targets [198], possibly causing the side effects like pleural effusions and suppression of the immune system observed in CML patients treated with this inhibitor [199].”
Long-term outcomes of dasatinib-induced pulmonary arterial hypertension: a population-based study
Weatherald, J. C., Chaumais, M., Savale, L., Jaïs, X., Seferian, A., Canuet, M., Bouvaist, H., Magro, P., Bergeron, A., Guignabert, C., et al. (2017) · European Respiratory Journal · doi:10.1183/13993003.00217-2017 · Cited by 146
Phosphoproteomics Identifies Driver Tyrosine Kinases in Sarcoma Cell Lines and Tumors
Bai, Y., Li, J., Fang, B., Edwards, A., Zhang, G., Bui, M. M., Eschrich, S. A., Altiok, S., Koomen, J. M., & Haura, E. B. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3015 · Cited by 137
Third-line therapy for chronic myeloid leukemia: current status and future directions
Cortes, J., & Lang, F. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01055-9 · Cited by 115
Role of Src Tyrosine Kinases in Experimental Pulmonary Hypertension
Pullamsetti, S. S., Berghausen, E. M., Dabral, S., Tretyn, A., Butrous, E., Savai, R., BUTROUS, G. S., Dahal, B. K., Brandes, R. P., Ghofrani, H. A., et al. (2012) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.112.248500 · Cited by 135
“Importantly, dasatinib apart from PDGFR/Abl and c-Kit also inhibits the structurally related Src family kinases (SFKs).(14) These 2 compounds are in clinical development for oncology indications.”
Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab
Dunn, E. F., Iida, M., Myers, R. A., Campbell, D. A., Hintz, K. A., Armstrong, E. A., Li, C., & Wheeler, D. L. (2011) · Oncogene · doi:10.1038/onc.2010.430 · Cited by 133
“Dasatinib, although relatively specific for ABL, BCR-ABL and the SFKs, possesses a broad spectrum of inhibition of kinases, including c-KIT, PDGFR, EphA receptors and several others (Hantschel et al., 2008).”
BackgroundPDGFR blockade is a rational and effective therapy for NPM-ALK–driven lymphomas
Laimer, D., Dolznig, H., Kollmann, K., Vesely, P. W., Schlederer, M., Merkel, O., Schiefer, A. I., Hassler, M. R., Heider, S., Amenitsch, L., et al. (2012) · Nature Medicine · doi:10.1038/nm.2966 · Cited by 134
Turn and Face the Strange: A New View on Phosphatases
Köhn, M. (2020) · ACS Central Science · doi:10.1021/acscentsci.9b00909 · Cited by 111
The structure of the leukemia drug imatinib bound to human quinone reductase 2 (NQO2)
Winger, J. A., Hantschel, O., Superti-Furga, G., & Kuriyan, J. (2009) · BMC Structural Biology · doi:10.1186/1472-6807-9-7 · Cited by 101
“Nevertheless, imatinib is remarkably specific, and is effective against a very limited set of tyrosine kinases, including Kit, PDGFR and DDR in addition to Abl [5].”
Self-citationThe Growing Arsenal of ATP-Competitive and Allosteric Inhibitors of BCR–ABL
Hantschel, O., Grebien, F., & Superti-Furga, G. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-1276 · Cited by 105
“classes of tyrosine kinases, such as the Src, Tec, Csk, and Eph families, aswell as several Ser/Thr kinases besidesABL1/2, KIT, PDGFRA/B, and DDR1/2 (7, 17).”
BackgroundSelf-citationCell Lineage-Based Stratification for Glioblastoma
Wang, Z., Sun, D., Chen, Y.-J., Xie, X., Shi, Y., Tabar, V. S., Brennan, C., Bale, T., Jayewickreme, C. D., Laks, D. R., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.06.003 · Cited by 111
“Dasatinib is a broad spectrum tyrosine kinase inhibitor (Hantschel et al., 2008).”
BackgroundProteomic Analysis Shows Synthetic Oleanane Triterpenoid Binds to mTOR
Yore, M. M., Kettenbach, A. N., Sporn, M. B., Gerber, S. A., & Liby, K. T. (2011) · PLoS ONE · doi:10.1371/journal.pone.0022862 · Cited by 98
“the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib, are, in fact more promiscuous than originally thought [72].”
BackgroundChoi, H., & Moon, A. (2018) · Archives of Pharmacal Research · doi:10.1007/s12272-018-1051-1 · Cited by 98
The BCR/ABL‐inhibitors imatinib, nilotinib and dasatinib differentially affect NK cell reactivity
Salih, J., Hilpert, J., Placke, T., Grünebach, F., Steinle, A., Salih, H. R., & Krusch, M. (2010) · International Journal of Cancer · doi:10.1002/ijc.25233 · Cited by 98
“effector cells.(7,8) All 3 BCR/ABL-inhibitors have been shown to inhibit T-cell activation and proliferation.”
BackgroundTyrosine kinase inhibitor imatinib augments tumor immunity by depleting effector regulatory T cells
Tanaka, A., Nishikawa, H., Noguchi, S., Sugiyama, D., Morikawa, H., Takeuchi, Y., Ha, D., Shigeta, N., Kitawaki, T., Maeda, Y., et al. (2020) · Journal of Experimental Medicine · doi:10.1084/jem.20191009 · Cited by 96
Haubeiss, S., Schmid, J. O., Mürdter, T. E., Sonnenberg, M., Friedel, G., van der Kuip, H., & Aulitzky, W. E. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-168 · Cited by 86
“In contrast to Imatinib, Nilotinib, and Sorafenib, Dasatinib targets a variety of other kinases such as Src kinases, TEC kinases, MAP kinases and others [18].”
BackgroundUnexpected Off-Targets and Paradoxical Pathway Activation by Kinase Inhibitors
Hantschel, O. D. (2014) · ACS Chemical Biology · doi:10.1021/cb500886n · Cited by 93
Self-citationCombining Immunotherapy with Oncogene-Targeted Therapy: A New Road for Melanoma Treatment
Aris, M., & Barrio, M. M. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00046 · Cited by 91
“VACCINES AND ONCOGENE-TARGETED THERAPIES Besides inhibiting target kinases in cancer cells, dasatinib also inhibits a wide variety of kinases, such as src, tec, syk, and gck-families, which are essential for immune system function (79).”
BackgroundMcAulay, K., Hoyt, E. A., Thomas, M. C., Schimpl, M., Bodnarchuk, M. S., Lewis, H. J., Barratt, D. G., Bhavsar, D., Robinson, D. M., Deery, M. J., et al. (2020) · Journal of the American Chemical Society · doi:10.1021/jacs.9b13391 · Cited by 91
“…is a high level of homology associated with c-KIT, PDGFR, and CSF-1R, 47,48 and ligands such as imatinib are known to inhibit both c-KIT and PDGFR. 49 More interestingly, PDGFR and c-KIT both contain a cysteine in the same position of the DFG region, and Winssinger et al. were able to demonstrate…”
BackgroundKim, T. D., Schwarz, M., Nogai, H., Grille, P., Westermann, J., Plöckinger, U., Braun, D., Schweizer, U., Arnold, R., Dörken, B., et al. (2010) · Thyroid · doi:10.1089/thy.2010.0251 · Cited by 79
“For patients with imatinib-resistance or -intolerance, two second-generation TKIs, nilotinib and dasatinib, are currently approved (19,20).”
Target spectrum of the BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia
Lee, H., Novitzky‐Basso, I., & Kim, D. D. H. (2021) · International Journal of Hematology · doi:10.1007/s12185-021-03126-6 · Cited by 82
“It also inhibits DDR1/2, which is related to immunity in some solid tumors, and oxidoreductase NQO2, which is a non-kinase protein related to potential drug–drug interactions [28].”
BackgroundJabbour, E. J., Hochhaus, A., Cortes, J. E., Rosée, P. G. L., & Kantarjian, H. M. (2009) · Leukemia · doi:10.1038/leu.2009.193 · Cited by 80
Stec, R., Grala, B., Ma̧czewski, M., Bodnar, L., & Szczylik, C. A. (2009) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-28-134 · Cited by 75
“Nilotinib like imatinib, inhibits BCR/ABL, CD 117, PDGFRA, NQO2, DDR1 [24,25,29].”
The transcription factor MITF is a critical regulator of GPNMB expression in dendritic cells
Gutknecht, M., Geiger, J., Joas, S., Dörfel, D., Salih, H. R., Müller, M. R., Grünebach, F., & Rittig, S. M. (2015) · Cell Communication and Signaling · doi:10.1186/s12964-015-0099-5 · Cited by 63
“Besides BCR-ABL, imatinib, nilotinib and dasatinib inhibit a variety of other kinases including c-Kit [24].”
BackgroundMartyanov, V., Kim, G.-H. J., Hayes, W., Du, S., Ganguly, B. J., Sy, O., Lee, S. K., Bogatkevich, G. S., Schieven, G. L., Schiopu, E., et al. (2017) · PLOS ONE · doi:10.1371/journal.pone.0187580 · Cited by 71
“This difference is arguably a reflection of the distinct kinase inhibitory spectra of dasatinib and nilotinib [58].”
BackgroundMechanisms of resistance to BCR-ABL and other kinase inhibitors
Lamontanara, A. J., Akçok, E. B. G., Kuzyk, O., & Hantschel, O. D. (2012) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2012.12.009 · Cited by 71
Self-citationCortes, J. E., Hochhaus, A., le Coutre, P. D., Rosti, G., Pinilla-Ibarz, J. A., Jabbour, E. J., Gillis, K., Woodman, R. C., Blakesley, R. E., Giles, F. J., et al. (2011) · Blood · doi:10.1182/blood-2010-11-318949 · Cited by 70
“Median duration of cumulative dose interruptions, d (range) 24 (1-345) 17 (4-234)”
BackgroundParseghian, C. M., Parikh, N. U., Wu, J. Y., Jiang, Z.-Q., Henderson, L., Tian, F., Pastor, B., Ychou, M., Raghav, K., Dasari, A., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-3138 · Cited by 67
“Although relatively specific for the Src and Abl family kinases, dasatinib possesses broad-spectrum inhibition of kinases including Kit, PDGFR, EphA receptors, and many others (19).”
BackgroundTsioumpekou, M., Cunha, S. I., Ma, H., Åhgren, A., Cedervall, J., Olsson, A., Heldin, C., & Lennartsson, J. (2019) · Theranostics · doi:10.7150/thno.37851 · Cited by 66
“The lack of therapeutic benefit of imatinib is counter intuitive, since it inhibits the activity of PDGFRβ as well as other kinases [47], hence one may have expected stronger anti-tumor effect by imatinib treatment.”
BackgroundActive site profiling reveals coupling between domains in SRC-family kinases
Krishnamurty, R., Brigham, J. L., Leonard, S. E., Ranjitkar, P., Larson, E. T., Dale, E. J., Merritt, E. A., & Maly, D. J. (2012) · Nature Chemical Biology · doi:10.1038/nchembio.1118 · Cited by 63
Ali, M. A. M. (2016) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-016-0208-1 · Cited by 60
Antagonistic functional duality of cancer genes
Stepanenko, A. A., Vassetzky, Y. S., & KAVSAN, V. M. (2013) · Gene · doi:10.1016/j.gene.2013.07.047 · Cited by 59
“…kinases (KIT, PDGFR, and DDR1), the oxidoreductase NQO2 as well as other Please cite this article as: Stepanenko, A.A., et al., Antagonistic function j.gene.2013.07.047 proteins at pharmacologically relevant concentrations (Breitkopf et al., 2010; Hantschel et al., 2008; Packer et al., 2011).”
InfluentialTwardowski, P. W., Beumer, J. H., Chen, C. S., Kraft, A. S., Chatta, G. S., Mitsuhashi, M., Ye, W., Christner, S. M., & Lilly, M. B. (2013) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e328361feb0 · Cited by 57
Hopkins, S., Linderoth, E., Hantschel, O., Suarez-Henriques, P., Pilia, G., Kendrick, H., Smalley, M. J., Superti-Furga, G., & Ferby, I. (2012) · Developmental Cell · doi:10.1016/j.devcel.2012.08.001 · Cited by 54
“While all inhibitors failed to rescue the Mig6-dependent apoptotic response, treatment with the specific second generation c-Abl inhibitor nilotinib (Tasigna) (Hantschel et al., 2008), prevented cell death in response to EGFR inactivation (Figure 2D).”
Self-citationKreutzman, A. S., Colom-Fernández, B., Marcos‐Jiménez, A., Ilander, M. M., Cuesta‐Mateos, C., Pérez-García, Y., Arévalo, C. D., Brück, O. E., Hakanen, H. H. E., Saarela, J., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0667 · Cited by 57
“In addition to BCR-ABL1, dasatinib inhibits a broad range of kinases, including members of the SRC, TEC, and SYK families (2).”
BackgroundSun, J., Wang, X., Tang, B., Liu, H., Zhang, M., Wang, Y., Ping, F., Ding, J., Shen, A., & Geng, M. (2018) · Theranostics · doi:10.7150/thno.23964 · Cited by 52
“To address this, we conducted a KinaseProfilerTM screening analysis (Table S1, 316 human kinases were involved) and mined the literature (including phosphoproteomics data to classify dasatinib binding kinases) to find the converged spectrum of kinases that are both targeted and inhibited by dasatinib [24-27].”
Pavlovsky, C., Chan, O., Talati, C., & Pinilla-Ibarz, J. A. (2018) · Future Oncology · doi:10.2217/fon-2018-0371 · Cited by 55
Rochat, B. (2009) · Current Cancer Drug Targets · doi:10.2174/156800909789056999 · Cited by 54
Mauro, M. J., Hughes, T. P., Kim, D.-W., Rea, D., Cortes, J. E., Hochhaus, A., Sasaki, K., Breccia, M., Talpaz, M., Ottmann, O., et al. (2023) · Leukemia · doi:10.1038/s41375-023-01860-w · Cited by 53
Development of an Effective Therapy for Chronic Myelogenous Leukemia
Woessner, D. W., Lim, C. S., & Deininger, M. W. (2011) · The Cancer Journal · doi:10.1097/ppo.0b013e318237e5b7 · Cited by 53
“30 Tyrosine kinase inhibitors are very effective inhibitors of BCR-ABL kinase activity; second-generation agents are more potent, and they have expanded inhibition against various BCRABL mutants resistant to the first-generation drug, imatinib.(31) As we mark a decade of imatinib use, we have developed an understandin…”
BackgroundÉderhy, S., Izzedine, H., Massard, C., Dufaître, G., Spano, J., Milano, G. A., Meuleman, C., Besse, B., Boccara, F., Kahyat, D., et al. (2011) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2011.01.009 · Cited by 52
Dasatinib promotes Th1-type responses in granzyme B expressing T-cells
Kreutzman, A. S., Ilander, M. M., Porkka, K., Vakkila, J., & Mustjoki, S. M. (2014) · OncoImmunology · doi:10.4161/onci.28925 · Cited by 49
Nilotinib impairs skeletal myogenesis by increasing myoblast proliferation
Contreras, O., Villarreal, M., & Brandan, E. (2018) · Skeletal Muscle · doi:10.1186/s13395-018-0150-5 · Cited by 47
c-Abl Inhibition Activates TFEB and Promotes Cellular Clearance in a Lysosomal Disorder
Contreras, P. S., Tapía, P., González-Hódar, L., Peluso, I., Soldati, C., Napolitano, G., Matarese, M., Heras, M. L., Valls, C., Martinez, A. N., et al. (2020) · iScience · doi:10.1016/j.isci.2020.101691 · Cited by 47
Advances and perspectives of proteolysis targeting chimeras (PROTACs) in drug discovery
Xi, J., Zhang, R., Chen, K., Yao, L., Li, M., Jiang, R., Li, X., & Fan, L. (2022) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2022.105848 · Cited by 47
Optimizing therapy for patients with chronic myelogenous leukemia in chronic phase
Kantarjian, H. M., Cortes, J. E., Rosée, P. G. L., & Hochhaus, A. (2010) · Cancer · doi:10.1002/cncr.24928 · Cited by 47
“ceptor 2 (EPHA2), KIT, PDGFR, and sarcoma (Src) family members(14); whereas nilotinib inhibits BCR-ABL, ABL, ARG, KIT, and PDGFR (Table 1).(15,16)”
BackgroundDrug target deconvolution by chemical proteomics
Raida, M. (2011) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2011.06.016 · Cited by 44
Potential utility of small tyrosine kinase inhibitors in the treatment of diabetes
Mokhtari, D., & Welsh, N. (2009) · Clinical Science · doi:10.1042/cs20090348 · Cited by 44
BCR-ABL Tyrosine Kinase Inhibitors: Which Mechanism(s) May Explain the Risk of Thrombosis?
Haguet, H., Douxfils, J., Chatelain, C., Graux, C., Mullier, F., & Dogné, J. (2018) · TH Open · doi:10.1055/s-0038-1624566 · Cited by 44
Novel Therapies in Acute Lymphoblastic Leukemia
Phelan, K. W., & Advani, A. S. (2018) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-018-0457-7 · Cited by 44
Targeting the integrin interactome in human disease
Vicente‐Manzanares, M., & Sánchez‐Madrid, F. (2018) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2018.05.010 · Cited by 43
Fachi, M. M., Tonin, F. S., Leonart, L. P., Rotta, I., Fernández-Llimós, F., & Pontarolo, R. (2019) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13933 · Cited by 43
“Our findings regarding nilotinib (both doses) demonstrate that this drug was less frequently associated with haematological grades 3–4 AEs, justified by its relatively high specificity and very narrow target spectrum.(61) Haematological toxicities are generally clinically significant and require temporary treatment in…”
BackgroundSchwarzbich, M.-A., Gutknecht, M., Salih, J., Salih, H. R., Brossart, P., Rittig, S. M., & Grünebach, F. (2012) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-011-1096-1 · Cited by 42
“Among the detected kinases were the cognate targets of the ABL (ABL and ARG) and SFK (SRC, LYN, YES and LCK) families of TKI [29, 33].”
BackgroundEadie, L. N., Hughes, T. P., & White, D. L. (2016) · PLoS ONE · doi:10.1371/journal.pone.0161470 · Cited by 41
“Accordingly, overexpression and activation of SFKs, such as LYN, are often observed in imatinib and nilotinib resistant cells, both in vitro[27–32] and in vivo[28, 30, 32, 33].”
BackgroundDysregulated Dscam levels act through Abelson tyrosine kinase to enlarge presynaptic arbors
Sterne, G. R., Kim, J. H., & Ye, B. (2015) · eLife · doi:10.7554/elife.05196 · Cited by 40
“Although frequently used to inhibit pathological increases in Abl activity in patients, nilotinib is known to have several off-targets, including c-Kit, PDGFR, Arg, NQ02, and DDR1 (Hantschel et al., 2008).”
BackgroundWaters, A. M., Khatib, T. O., Papke, B., Goodwin, C. M., Hobbs, G. A., Diehl, J. N., Yang, R. Y., Edwards, A. C., Walsh, K. H., Sulahian, R., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109291 · Cited by 39
“Whereas the currently approved ATP-competitive SRC inhibitor dasatinib has activities against at least 68 other protein kinases (Hantschel et al., 2008), KX2-391 is both a more potent and more selective SRC inhibitor.”
BackgroundOff-Target Effects of BCR-ABL and JAK2 Inhibitors
Green, M. R., Newton, M., & Fancher, K. M. (2013) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000000023 · Cited by 38
Global Approaches To Study Protein–Protein Interactions Among Viruses and Hosts
Mendez-Rios, J. D., & Uetz, P. (2010) · Future Microbiology · doi:10.2217/fmb.10.7 · Cited by 37
Leonard, J. T., Kosaka, Y., Malla, P., LaTocha, D. H., Lamble, A. J., Hayes‐Lattin, B., Byrd, K., Druker, B. J., Tyner, J. W., Chang, B. H., et al. (2020) · Blood · doi:10.1182/blood.2020005655 · Cited by 36
Regorafenib in gastrointestinal stromal tumors: clinical evidence and place in therapy
Ferraro, D. A., & Zalcberg, J. R. (2014) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834014544892 · Cited by 36
“Imatinib is able to bind in a reversible manner to the adenosine triphosphate (ATP) binding pocket of ABL, KIT, PDGFRA and PDGFRB, which prevents pathway activation and inhibits growth of tumor cells [Hantschel et al. 2008].”
BackgroundIa, K. K., Mills, R. D., Hossain, M. I., Chan, K., Jarasrassamee, B., Jorissen, R. N., & Cheng, H. (2010) · Growth Factors · doi:10.3109/08977194.2010.484424 · Cited by 35
“In addition to efficiently inhibiting SFKs, these inhibitors can also inhibit the activity of many other protein kinases and non-kinase cellular proteins [91].”
BackgroundWie, S. M., Adwan, T. S., DeGregori, J. V., Anderson, S. M., & Reyland, M. E. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.551366 · Cited by 35
“ParC5 cells were treated with H2O2 alone or following pretreatment with dasatinib, a broad spectrum TKI that inhibits both c-Abl and SFKs (29, 30).”
InfluentialNovel Bruton's tyrosine kinase inhibitors currently in development
Uckun, F. M., & D'Cruz (2013) · OncoTargets and Therapy · doi:10.2147/ott.s33732 · Cited by 34
“Noncovalent Btk inhibitors Dasatinib (Sprycel) Dasatinib (Sprycel/BMS-354825, Bristol-Myers Squibb) [N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl) piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole5-carboxamide], is a potent, orally active, multikinase BCR/Abl and Src family TKI that is FDA-approved for treat…”
X‐Ray Crystal Structure of Bone Marrow Kinase in the X Chromosome: A Tec Family Kinase
Muckelbauer, J. K., Sack, J. S., Ahmed, N., Burke, J. R., Chang, C. Y., Gao, M., Tino, J. A., Xie, D., & Tebben, A. J. (2011) · Chemical Biology & Drug Design · doi:10.1111/j.1747-0285.2011.01230.x · Cited by 32
Somatic DNA mutation analysis in targeted therapy of solid tumours.
Yu, B., O'Toole, S. A., & Trent, R. J. (2015) · PubMed Central · doi:10.3978/j.issn.2224-4336.2015.04.04 · Cited by 33
“It reversely binds to the ATP binding pocket of the KIT or ABL kinase and locks it in a self-inhibited conformation (61).”
BackgroundShort, N. J., Kantarjian, H. M., Jabbour, E. J., & Ravandi, F. (2017) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2017.05.001 · Cited by 32
Hantschel, O. D., Gstöttenbauer, A., Colinge, J., Kaupe, I., Bilban, M., Burkard, T. R., Valent, P., & Superti‐Furga, G. (2008) · Molecular Oncology · doi:10.1016/j.molonc.2008.07.003 · Cited by 32
“…tyrosine kinases, including the Src kinase family and Btk/Tec, and many serine/threonine kinases (Carter et al., 2005; Bantscheff et al., 2007; Hantschel et al., 2007; Rix et al., 2007), nilotinib can be considered the most specific Bcr–Abl inhibitor currently available (Hantschel et al., 2008).”
BackgroundSelf-citationRosti, G., Castagnetti, F., Gugliotta, G., Palandri, F., Martinelli, G., & Baccarani, M. (2010) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428191003637282 · Cited by 30
“Nilotinib has no significant activity toward Src, FMS-like tyrosine kinase 3 (FLT-3), vascular endothelial growth factor, or epidermal growth factor receptor tyrosine kinases at concentrations53000 nM [7,8].”
BackgroundMechanisms of Resistance to Targeted Therapies in Chronic Myeloid Leukemia
Lussana, F., Intermesoli, T., Stefanoni, P., & Rambaldi, A. (2017) · Handbook of experimental pharmacology · doi:10.1007/164_2017_81 · Cited by 30
Kreutzman, A. S., Jaatinen, T., Greco, D., Vakkila, E., Richter, J., Ekblom, M., Hjorth‐Hansen, H., Stenke, L., Melo, T., Paquette, R. L., et al. (2012) · Experimental Hematology · doi:10.1016/j.exphem.2012.07.007 · Cited by 30
“Dasatinib has a unique and broader kinase-inhibition profile compared with imatinib [12].”
BackgroundTyrosine kinase inhibitor therapy in chronic myeloid leukemia: update on key adverse events
Carneiro, B. A., Kaplan, J. B., & Giles, F. J. (2015) · Expert Review of Hematology · doi:10.1586/17474086.2015.1041910 · Cited by 29
O’Hare, T., Eide, C. A., Agarwal, A., Adrian, L. T., Zabriskie, M. S., MacKenzie, R. J., LaTocha, D. H., Johnson, K. J., You, H., Luo, J., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3904 · Cited by 29
AlAsfoor, S., Rohm, T. V., Bosch, A. J. T., Dervos, T., Calabrese, D., Matter, M. S., Weber, A., & Cavelti‐Weder, C. (2018) · Scientific Reports · doi:10.1038/s41598-018-32853-w · Cited by 29
Kreutzman, A. S., Yadav, B., Brümmendorf, T. H., Gjertsen, B. T., Lee, M. H., Janssen, J. J. W. M., Kasanen, T., Koskenvesa, P., Lotfi, K., Markevärn, B., et al. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1638210 · Cited by 28
“Bosutinib also has a wider TK inhibitory profile than imatinib and thus more resembles dasatinib, another second-generation TKI, in the sense that for example, both inhibit the SRC kinase family.(7,8) Interestingly, previous reports from our group and others have shown significant immunomodulatory effects of dasatinib.”
BackgroundInfluentialYES1 amplification confers trastuzumab–emtansine (T-DM1) resistance in HER2-positive cancer
Wang, L., Wang, Q., Xu, P., Li, F., Li, Y., Fu, H., Quan, H., & Lou, L. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-0952-1 · Cited by 28
Rizwan, M., Selvanathan, V., Rasool, A., Qureshi, M. A. U. R., Iqbal, D. N., Kanwal, Q., Shafqat, S. S., Rasheed, T., & Bilal, M. (2022) · Water Air & Soil Pollution · doi:10.1007/s11270-022-05904-2 · Cited by 28
“IMA inhibits numerous tyrosine kinase enzymes by the occupation of TK sites (Hantschel et al., 2008).”
BackgroundIrvine, E., & Williams, C. B. (2013) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1266 · Cited by 28
“Indeed, dasatinib can bind more than 65 different targets (Table 1).(7) Dasatinib is nevertheless highly selective for BCR-ABL1, with in vitro affinity of dasatinib for BCR-ABL1 that is more than 300 times greater than that of imatinib.”
BackgroundInfluentialMYC inhibitors in multiple myeloma
Martínez-Martín, S., & Soucek, L. (2021) · Cancer Drug Resistance · doi:10.20517/cdr.2021.55 · Cited by 27
Metadata
- Authors
- Hantschel, O., Rix, U., & Superti-Furga, G.
- Affiliations
- Austrian Academy of Sciences (AT)
- Venue
- Leukemia & Lymphoma
- Publisher
- Informa UK Limited
- Published
- 2008-01
- Volume
- 49
- Issue
- 4
- Pages
- 615-619
- ISSN
- 1026-8022 (ISSN-L)
- 1042-8194
- 1029-2403
- OpenAlex
- W2034862875
- Cited by
- 256
- References
- 17
- Citations by year
- 2026: 2 · 2025: 6 · 2024: 4 · 2023: 14 · 2022: 15 · 2021: 14 · 2020: 21 · 2019: 10 · 2018: 16 · 2017: 19 · 2016: 10 · 2015: 17 · 2014: 15 · 2013: 19 · 2012: 23
- FWCI
- 11.04
- Type
- journal article
- Language
- en
- Open access
- green
- infoscience.epfl.ch
- Locations
- Leukemia & lymphoma/Leukemia and lymphoma (publishedVersion)
- PubMed (publishedVersion)
- Infoscience (Ecole Polytechnique Fédérale de Lausanne) (submittedVersion)
- Infoscience (Ecole Polytechnique Fédérale de Lausanne) (submittedVersion, cc-by-nc-nd)
- Topics
- Health Sciences › Medicine › Hematology › Chronic Myeloid Leukemia Treatments
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Keywords
- BCR-ABL tyrosine kinase inhibitors, imatinib, nilotinib, dasatinib, chronic myeloid leukemia, target specificity, imatinib resistance, second-generation tyrosine kinase inhibitors
- MeSH terms
- Imatinib Mesylate, Dasatinib, Benzamides, Humans, Piperazines, Pyrimidines, Thiazoles, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Fusion Proteins, bcr-abl, Drug Delivery Systems, Protein Kinase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.